Objective: Comorbidity is a debated prognosticator in lung cancer. Results are conflicting, and the variety in study designs and inclusion criteria hampers direct comparison of available studies. So far, methods for generation of data on lung cancer comorbidity have attracted little attention. We evaluated whether self-reported comorbidity and registerbased comorbidity are of comparable quality.
Introduction
Lung cancer is one of the world's most prevalent cancer types, with an overall poor prognosis. 1 In highincome countries, it is primarily diagnosed in patients age 65 years or older, and the diagnosis remains heavily associated with smoking. 2 It is therefore unsurprising that patients with lung cancer also commonly have other medical conditions (comorbidities). 3 Comorbidity has been established as a predictor of poor prognosis in a number of cancers. 4 Hence, it affects the outcome in several ways (for example, by causing delay in diagnosis and by influencing the choice of antineoplastic treatment), and patients with lung cancer have a reduced tolerance of treatment. [5] [6] [7] However, reports on the impact of comorbidity on lung cancer survival are conflicting. 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] This may partly be explained by cohort variation, as reported cohorts include large population studies with several thousands of unselected patients as *Corresponding author.
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well as highly selected participants in clinical trials. So far, an association between comorbidity and survival has been observed, especially in population-based studies. However, whether the impact of comorbidity can be ascribed to individual medical conditions or to the sum of comorbid conditions present remains unclear. In clinical trials, results describing the association of comorbidity with survival have been conflicting. [10] [11] [12] [13] 16, [18] [19] [20] Furthermore, comorbidity studies rarely describe their data collection methods (i.e., whether data were collected in real time from medical records or came from audited national registers), and this evidently hampers comparison of extant studies. Surprisingly little effort has been devoted to studying the potential bias that may spring from the manner in which the collection of data on comorbidity is obtained and how this may bias the association between lung cancer survival and comorbidity. Therefore, it is important to clarify whether the quality of comorbidity data depends on the data collection method used.
To assess comorbidity, several risk scores have been developed. In lung cancer, the two comorbidity risk scores most frequently used are the Charlson comorbidity index (CCI) and the Colinet simplified comorbidity score (SCS). The CCI was developed in 1984 on the basis of a cohort of hospitalized patients. It includes 19 different diseases, each of which is weighted with from 1 to 6 points according to the risk for mortality. 24 The SCS was developed in 2005 as a simplification of the CCI directed toward patients with lung cancer. It includes six different diseases, as well as smoking history, and each of these factors is weighted with 1 to 7 points. 25 The primary objective of this prospective cohort study was to elucidate whether data collection affects comorbidity assessment by comparing self-reported comorbidity with register-based comorbidity in patients in whom lung cancer is suspected. Furthermore, we wanted to evaluate whether any difference between the selfreported and the register-based comorbidity and the derived CCI and SCS risk scores would influence the association between comorbidity and overall survival (OS) in patients with lung cancer.
Material and Methods

Patients
This was a prospective cohort study of patients referred to the Department of Pulmonary Medicine, Aarhus University Hospital, Denmark (N ¼ 1735). The cohort has been studied in other contexts for epidermal growth factor system and exosome analyses. [26] [27] [28] In short, patients with suspected lung cancer who were referred to the department between April 2011 and September 2014 were included. Patients with a final diagnosis of NSCLC or SCLC defined the lung cancer group (n ¼ 336). The first 125 patients determined to be cancer-free defined the control group. Patients with other types of cancer were excluded, as were patients without a prediagnostic blood sample. For detailed information on the inclusion and exclusion of the patients, see Sandfeld-Paulsen et al. 27 
Data
Data on comorbidity in both patients without cancer and patients with lung cancer were obtained from the Danish National Patient Registry (NPR) and as selfreported comorbidity. Since 1977, the NPR has been collecting data on all admissions to Danish hospitals. For each patient, the dates of admission and discharge, as well as the discharge diagnoses, are recorded in this registry. From the NPR, all discharge diagnoses between January 1, 1977 , and the end of the study period (December 31, 2016) were retrieved. Self-reported comorbidity was collected as follows: before the first consultation, patients were asked to state their present and previous comorbidities, and at the first consultation, the consultant would register the comorbidities. This information was based on a questionnaire sent to the patient before the first consultation. In the questionnaire, the patient was invited to state any known disease within the areas covered in the CCI. The consultant was free to add any comorbidity that had been missed by the patient. Comorbidity was then assessed by using the individual comorbidities, the CCI, and the SCS. The CCI was categorized as none (score 0), mild (score 1 or 2), medium (score 3 or 4), or severe (score >5). The SCS was categorized as none (score 0-7), mild (score 8 or 9), medium (score 10 or 11), or severe (score >12). The following clinicopathological characteristics were collected at the time of inclusion: histological subtype, stage, WHO performance status (PS), smoking, age, and sex. Date of death was obtained from the Danish Civil Registration System.
Statistical Analyses
Baseline characteristics were compared between patients with and without cancer by using the chisquare and Kruskal-Wallis tests. Self-reported and NPR-registered comorbidities were compared by number of agreement, and the reliability between data sets was estimated by using Cohen's k coefficient. OS was calculated from the date of inclusion to the date of death. Patients who were still alive on December 31, 2016, were censored. Crude and adjusted analyses were performed using the Cox proportional hazard model. Confounder-adjusted analyses included age, sex, and smoking. However, because smoking was already included in the SCS score, it was not included as a confounder when evaluating the SCS. The selection of confounders was based on a directed acyclic graph (DAG) (Fig. 1 ). PS and stage were included in the model as effect modifiers. All tests were two sided, and a p value less than 0.05 was considered significant. The analyses were performed with the statistical software STATA, version 14.0 (StataCorp LP, College Station, TX).
Ethics
All patients gave informed written consent, and the Central Denmark Region Committees on Biomedical Research Ethics (journal no. M-20100246) and the Danish Data Protection Agency approved the study (journal no. 2010-41-5437).
Results
A total of 461 patients were included in this study: 336 patients with lung cancer and 125 without lung cancer (see Table 1 for patient characteristics). At the time of follow-up, 19 of 125 patients without cancer had died and 255 of 336 patients with lung cancer had died. The median follow-up period for patients who were still alive was 5.3 years.
Data on self-reported comorbidity and NPR-reported comorbidity were collected and compared. Table 2 shows the agreement between these two methods of collecting comorbidity information for each observed comorbidity. Despite an agreement percentage of only 38%, diabetes is the comorbidity for which agreement between the NPR and the self-reported data sets was highest.
On the basis of the self-reported and the NPR-based information, the CCI and SCS were calculated ( Table 3) . Independently of the risk score for both CCI and SCS, an asymmetry in the data sets was observed where the NPR comorbidity values exceeded the self-reported comorbidity values (Tables 4 and 5 ). For comorbidity evaluated from the CCI, no patients had a self-reported CCI score of 5 or higher and only five patients had a selfreported CCI score of 4. Inversely, for comorbidity evaluated from the NPR, 26 patients had a CCI score of 5 or higher and 27 patients had a CCI score of 4. The reliability between self-reported and NPR CCI value (k) was 0.34 with an expected agreement of 39% and an observed agreement of 60%, which corresponds to no more than fair agreement. 29 The same trend was seen when assessing comorbidity using the SCS, in which case 21 patients with a self-reported SCS less than 12 had an NPR-reported SCS higher than 12. The reliability between self-reported and NPR-based SCS (k) was 0.42 with an expected agreement of 41% and an observed agreement of 68%, which corresponds to fair agreement. 29 Because which of the two data collection methods actually measures the true comorbidity remains unknown, a joint comorbidity score was calculated on the basis of the self-reported and the NPR-based information; if the individual comorbidity was present in either of the data sets, the comorbidity was considered present. On the basis of this new joint comorbidity data set, the CCI and the SCS were calculated and compared to evaluate the agreement between the scores for estimation of comorbidity (see Table 4 ). The reliability between the SCS and the CCI (k) was 0.54 with an expected agreement of 34% and an observed agreement of 64%, which corresponds to a fair agreement. 29 To evaluate whether the differences observed in the data sets were of any clinical relevance, survival analyses were performed. On the basis of self-reported and NPRbased data sets and the joint comorbidity data set, comorbidity was assessed from the CCI and the SCS. The crude and adjusted hazard ratios (HRs) are shown in Table 6 . Our results show that CCI is not associated with survival, irrespective of the data collection method used. The opposite is observed for SCS: when information was collected from the NPR, comorbidity was associated with survival in patients with lung cancer. The impact found in the univariate analysis (HR ¼ 1.6, 95% confidence interval [CI]: 1.0-2.5, p ¼ 0.03) was confirmed in the multivariate analysis ((HR ¼ 1.9, 95% CI: Directed acyclic graph of the association between comorbidity and survival. Black arrows are factors with an impact on comorbidity and/or survival. Red arrows are factors shown to exert effect modification of the connection between comorbidity and survival. From this directed acyclic graph, the minimally sufficient adjustment sets of confounders for estimating the total effect of comorbidity on survival are age, sex, and smoking. Performance status (PS) and stage of the disease should be included in the final model as effect modifiers. To evaluate whether any impact of an individual comorbidity was lost when summing up the total comorbidity status, each individual comorbidity was analyzed. The crude and adjusted HRs of this analysis are shown in Supplementary Table 1. This part of the study was also conducted in the noncancer group to validate the comorbidities with an expected impact on survival. Diabetes was the only individual comorbidity in the univariate analysis that had a significant prognostic value for patients with lung cancer (HR¼1.6, 95% CI: 1.1-2.4, p ¼ 0.013). However, the prognostic value of diabetes in patients with lung cancer was lost in the multivariate analyses.
Because the cohort consisted entirely of patients with lung cancer, it was split on the basis of histological subtypes, and the association of the clinicopathological characteristics with OS was evaluated as univariate associations (Supplementary Table 2 ). The association remained significant in the nonsquamous cell lung cancer group, whereas the significance was lost in the lower-numbered squamous cell and SCLC groups.
Discussion
In this prospective cohort study of 336 patients with lung cancer, we found that self-reported comorbidity was underreported compared with NPR-registered comorbidity. We also found that the impact of comorbidity on survival was smaller among patients with lung cancer than among patients in whom lung cancer was suspected but who were determined to be without cancer. Most importantly, we demonstrated that the data collection method can affect the association between comorbidity and survival. These are novel findings.
In lung cancer, some studies have reported comorbidity to be an independent prognostic marker of poor survival, 8, 9, 13, 14, [18] [19] [20] [21] [22] 30 whereas other studies report no such association. [10] [11] [12] [13] This discordance may be explained by the methods used for patient selection or the methods used to report comorbidity. Comorbidity has been associated with poor survival of lung cancer in population-based studies 8, 14, [21] [22] [23] 30 ; however, in clinical trials the results are not uniform. 9, 12, 13, [16] [17] [18] [19] [20] The main advantage of reporting such associations on the basis of population studies is that they include all patients independently of their stage of disease, PS, and eligibility for cancer treatment. The disadvantage of populationbased studies, on the other hand, is that they fail to address confounding factors such as PS, smoking, or lifestyle. This is in contrast to studies of patients from clinical trials, in which the amount of information that can be obtained is higher. In clinical trials, however, patients are often highly selected, for example, according to PS or particular comorbidities, and patients with the highest comorbidity burdens are therefore often excluded. In the present study, we included patients in whom lung cancer was suspected at the time of their referral. This allowed us to include patients independently of their comorbidity burden, and any bias based on patient selection was therefore avoided. Another explanation of the divergent findings reported in previous studies could involve the way in which comorbidity data were collected and the reliability of these data and data registration methods. Danish register-based studies are generally known to enjoy high reliability because of the high quality of Danish public registers. 31, 32 Nevertheless, using recorded data from hospital findings introduces an inherent bias because comorbidity will be registered only for patients who have actually been hospitalized. Furthermore, the individual's comorbidity must lie above a certain threshold to be registered. In other words, if the patient has a comorbidity that is diagnosed and treated by the general practitioner, this comorbidity will not necessarily be registered in national registers. In most of the clinical trials, how data were collected is unclear, and a direct comparison of the results of such studies is therefore not possible. We collected data both from the NPR and from self-reported data, which makes a direct comparison of the data collection methods feasible. Still, the present study was made possible only because we could draw on Danish registers with valid data and detailed information about each patient. By asking the patient, one would expect to receive full information on any comorbidity irrespective of its severity. We accordingly expected that the selfreported comorbidity would exceed the NPR-based comorbidity. Surprisingly, we found the opposite, with an underreporting of the self-reported comorbidities compared with the NPR-registered comorbidities. We speculate that this could be due to the situation in which the patient was faced with a suspicion of severe disease and therefore wanted to appear to be in a condition warranting treatment. Another, perhaps more plausible, explanation may be that the patient unintentionally reported only those comorbidities that affected daily living. Furthermore, the hospital staff had not received special instructions on how to obtain the information on comorbidity. By informing and educating the hospital staff on the importance of comorbidity and how to obtain such information, it is likely that the focus on comorbidity would increase and, in turn, that the quality of information on self-reported comorbidity would also increase. In countries without good systems for registering comorbidity, it may be necessary to develop a comorbidity questionnaire listing possible prognostic comorbidities and to present patients with detailed questions to obtain full information on comorbidity.
We then evaluated whether the different data collection methods could affect the OS outcome. We evaluated comorbidity by using the two most commonly used risk scores in lung cancer: the CCI and the SCS. When adjusting for the clinicopathological characteristics, we had to define which of the characteristics were confounding the association between comorbidity and survival. PS is of special interest because both comorbidity and stage of the disease can affect the patient's PS. The question is therefore whether a patient has a poor PS because of the cancer stage, whether the PS is poor because of the patient's comorbidity, or because of a combination of the two. On the basis of directed acyclic graph analyses (see Fig. 1 ), we found that the variables sex, age, and smoking were confounders in the association between comorbidity and survival whereas stage and PS were effect modifiers and should be included in the final model as such. This represents a step in the evaluation of comorbidity that is rarely well described but affects the outcome tremendously. We found that severe comorbidity was associated with poor survival, though only when the SCS risk score was used and only when calculations were based on the NPR data. When using the self-reported data and the CCI risk score, we found no impact on survival. Whether the CCI is outdated in view of recent developments in medicine in general (for example, the development of anti-human immunodeficiency virus treatments and improvements in the management of coronary artery disease) is being debated. 25, 33 The SCS, which is specific for patients with lung cancer, has therefore been introduced as a replacement for the CCI. In the SCS, the weighting of the components varies considerably, with tobacco being the component with most impact (7 points) (see Table 3 ). In the studies evaluating the SCS, there is no consensus on the cutpoints defining high comorbidity, which could also lead to variation in the reported results. 10, 12, 25, 23 In a review of the effect of comorbidity on cancer survival, patients with lung cancer had a 5-year survival rate that was only minimally affected by comorbidity compared with patients with other cancer diagnoses. 34 This could be explained by the poor survival of patients with lung cancer in general. In line with these findings, in our study we detected only a minimal impact of comorbidity on survival. To evaluate whether our findings were biased by a single comorbidity having a major impact on OS, survival analyses were performed on the individual comorbidities as well. This part of the study was performed in the lung cancer group and in the noncancer group as well. The noncancer group here served only as a reference group, and the results should be interpreted with caution because the noncancer group was very heterogeneous and the number of patients was very low. As the firstever study of its kind, the present study demonstrates a gap between the doctor's record and the patient's own perception of her or his disease. This is important information not only when conducting studies on comorbidity but especially for hospital staff working with patients with lung cancer in the clinic. In the future, it would be interesting to explore the origins of this gap and, more importantly, how we could narrow it.
Additionally, it would be interesting to evaluate patients' own perceptions of comorbidity, life expectancy, and quality of life. Finally, comorbidity studies of patients without cancer but with other severe lifeshortening conditions are needed.
In conclusion, the results of comorbidity studies in lung cancer have produced conflicting results. Because of differences in the inclusion criteria, data collection methods, and variables included as confounders, direct comparison has not been possible. We have demonstrated that the agreement between self-reported and NPR-based comorbidity is poor. Furthermore, we have shown that this disagreement may affect the estimated association between comorbidity and OS in patients with lung cancer.
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